CPC Advisors LLC Increases Position in Merck & Co., Inc. $MRK

Key Points

• CPC Advisors LLC boosted its stake in Merck by 1,728.8% in Q4, acquiring an additional 64,641 shares to hold 68,380 shares worth about $7.20 million.
• Shares slid about 3.8% after a Merck/Eisai combination therapy for advanced renal cell carcinoma failed to meet primary endpoints, creating near‑term oncology uncertainty despite recent regulatory wins including FDA approval of IDVYNSO and a priority review for KEYTRUDA.
• Merck beat Q4 estimates with $2.04 EPS and $16.4B revenue (up 5% y/y), set FY2026 guidance at 5.00–5.15 EPS, and pays a quarterly dividend of $0.85 (approximately a 3.0% yield).

CPC Advisors LLC grew its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 1,728.8% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 68,380 shares of the company's stock after buying an additional 64,641 shares during the period. CPC Advisors LLC's holdings in Merck & Co., Inc. were worth $7,198,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in MRK. Brighton Jones LLC raised its holdings in shares of Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company's stock valued at $3,808,000 after buying an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Merck & Co., Inc. by 52.2% in the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company's stock valued at $910,000 after buying an additional 3,941 shares during the last quarter. Diversify Advisory Services LLC raised its holdings in shares of Merck & Co., Inc. by 94.1% in the second quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company's stock valued at $2,590,000 after buying an additional 15,636 shares during the last quarter. Diversify Wealth Management LLC raised its holdings in shares of Merck & Co., Inc. by 22.2% in the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company's stock valued at $3,054,000 after buying an additional 6,897 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Merck & Co., Inc. by 111.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company's stock valued at $53,918,000 after buying an additional 359,356 shares during the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Trading Down 3.8%

Shares of Merck & Co., Inc. stock opened at $112.63 on Wednesday. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. The company's 50-day simple moving average is $119.02 and its 200-day simple moving average is $106.48. The firm has a market cap of $278.18 billion, a price-to-earnings ratio of 15.47, a price-to-earnings-growth ratio of 2.35 and a beta of 0.26.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. During the same period in the previous year, the business posted $1.72 earnings per share. The business's revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 4.93 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th were given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 3.0%. The ex-dividend date was Monday, March 16th. Merck & Co., Inc.'s dividend payout ratio is presently 46.70%.

Wall Street Analyst Weigh In

MRK has been the subject of a number of research reports. Wall Street Zen raised shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating in a report on Saturday, March 28th. Wells Fargo & Company boosted their price target on shares of Merck & Co., Inc. from $135.00 to $150.00 and gave the stock an "overweight" rating in a research note on Thursday, March 12th. Citigroup boosted their price target on shares of Merck & Co., Inc. from $120.00 to $125.00 and gave the stock a "neutral" rating in a research note on Friday, March 20th. Zacks Research upgraded shares of Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 17th. Finally, Guggenheim boosted their price target on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a "buy" rating in a research note on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $128.47.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, CMO Chirfi Guindo sold 20,000 shares of the company's stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $121.88, for a total value of $2,437,600.00. Following the sale, the chief marketing officer owned 80,615 shares of the company's stock, valued at $9,825,356.20. This represents a 19.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Richard R. Deluca sold 37,685 shares of the firm's stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the transaction, the executive vice president directly owned 160,174 shares of the company's stock, valued at approximately $19,368,240.08. This trade represents a 19.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 320,176 shares of company stock valued at $38,281,735 in the last ninety days. Company insiders own 0.09% of the company's stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA approves IDVYNSO (doravirine/islatravir), a once‑daily two‑drug HIV single‑tablet regimen for virologically suppressed adults — adds a new, potentially valuable HIV product to Merck’s commercial portfolio. FDA Approves Merck's Once-Daily IDVYNSO™ (doravirine/islatravir)
• Positive Sentiment: FDA grants priority review to supplemental BLAs for KEYTRUDA (and KEYTRUDA QLEX) in combination with Padcev for cisplatin‑eligible muscle‑invasive bladder cancer — a regulatory fast track that could meaningfully expand Keytruda’s labeled uses if approved. FDA Grants Priority Review for KEYTRUDA® … with Padcev®
• Positive Sentiment: EU approves ENFLONSIA for infant RSV protection — another vaccine/antibody approval that broadens Merck’s preventive‑care offerings and potential pediatric revenue streams. Merck Wins EU Approval for ENFLONSIA to Protect Infants from RSV
• Neutral Sentiment: Merck launched a portfolio of bio‑based HPLC solvents (sustainability / product‑line extension) — small commercial impact but supportive of ESG/industrial positioning. Merck Launches First Bio-Based Solvent Portfolio for High-Performance Liquid Chromatography
• Negative Sentiment: Merck/Eisai combination therapy in advanced renal cell carcinoma failed to meet primary endpoints in a late‑stage study — a significant clinical setback that likely prompted today’s selling pressure and raises questions about near‑term oncology growth assumptions. Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
• Negative Sentiment: Corporate update on the Phase 3 LITESPARK‑012 trial (Merck/Eisai) accompanies the failure, reinforcing the clinical disappointment and near‑term uncertainty for that program. Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.